230 related articles for article (PubMed ID: 24698864)
1. Rifaximin for episodic, overt hepatic encephalopathy: the data are catching up to clinical practice, but questions remain.
Congly SE; Leise MD
Am J Gastroenterol; 2014 Apr; 109(4):598. PubMed ID: 24698864
[No Abstract] [Full Text] [Related]
2. ACP Journal Club. Adding rifaximin to lactulose increased reversal and decreased mortality in hepatic encephalopathy.
Kowdley KV; Burman BE
Ann Intern Med; 2013 Oct; 159(8):JC8. PubMed ID: 24126669
[No Abstract] [Full Text] [Related]
3. Efficacy of rifaximin versus lactulose for reducing the recurrence of overt hepatic encephalopathy and hopitalizations in cirrhosis.
Irimia R; Trifan A
Rev Med Chir Soc Med Nat Iasi; 2012; 116(4):1021-7. PubMed ID: 23700882
[TBL] [Abstract][Full Text] [Related]
4. Comparison of Rifaximin Plus Lactulose with the Lactulose Alone for the Treatment of Hepatic Encephalopathy.
Ahire K; Sonawale A
J Assoc Physicians India; 2017 Aug; 65(8):42-46. PubMed ID: 28799305
[TBL] [Abstract][Full Text] [Related]
5. A randomized, double-blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of overt hepatic encephalopathy.
Sharma BC; Sharma P; Lunia MK; Srivastava S; Goyal R; Sarin SK
Am J Gastroenterol; 2013 Sep; 108(9):1458-63. PubMed ID: 23877348
[TBL] [Abstract][Full Text] [Related]
6. The cost-effectiveness and budget impact of competing therapies in hepatic encephalopathy - a decision analysis.
Huang E; Esrailian E; Spiegel BM
Aliment Pharmacol Ther; 2007 Oct; 26(8):1147-61. PubMed ID: 17894657
[TBL] [Abstract][Full Text] [Related]
7. Hospitalizations during the use of rifaximin versus lactulose for the treatment of hepatic encephalopathy.
Leevy CB; Phillips JA
Dig Dis Sci; 2007 Mar; 52(3):737-41. PubMed ID: 17245628
[TBL] [Abstract][Full Text] [Related]
8. [Intestine specific broad spectrum antibiotic. Rifaximin: therapy option in hepatic encephalopathy].
MMW Fortschr Med; 2014 Feb; 156(3):64-5. PubMed ID: 24938070
[No Abstract] [Full Text] [Related]
9. Response to Congly and Leise.
Praveen S; Chander SB
Am J Gastroenterol; 2014 Apr; 109(4):598-9. PubMed ID: 24698865
[No Abstract] [Full Text] [Related]
10. Is Lactulose Plus Rifaximin Better than Lactulose Alone in the Management of Hepatic Encephalopathy?
Butt NI; Butt UI; Kakar AATK; Malik T; Siddiqui AM
J Coll Physicians Surg Pak; 2018 Feb; 28(2):115-117. PubMed ID: 29394969
[TBL] [Abstract][Full Text] [Related]
11. Lactulose, rifaximin or branched chain amino acids for hepatic encephalopathy: what is the evidence?
Gluud LL; Dam G; Borre M; Les I; Cordoba J; Marchesini G; Aagaard NK; Vilstrup H
Metab Brain Dis; 2013 Jun; 28(2):221-5. PubMed ID: 23275147
[TBL] [Abstract][Full Text] [Related]
12. Optimal treatment of hepatic encephalopathy.
Waghray A; Waghray N; Kanna S; Mullen K
Minerva Gastroenterol Dietol; 2014 Mar; 60(1):55-70. PubMed ID: 24632768
[TBL] [Abstract][Full Text] [Related]
13. Analysis of hospitalizations comparing rifaximin versus lactulose in the management of hepatic encephalopathy.
Neff GW; Kemmer N; Zacharias VC; Kaiser T; Duncan C; McHenry R; Jonas M; Novick D; Williamson C; Hess K; Thomas M; Buell J
Transplant Proc; 2006 Dec; 38(10):3552-5. PubMed ID: 17175328
[TBL] [Abstract][Full Text] [Related]
14. Should We Treat Minimal/Covert Hepatic Encephalopathy, and with What?
Henderson PK; Herrera JL
Clin Liver Dis; 2015 Aug; 19(3):487-95. PubMed ID: 26195203
[TBL] [Abstract][Full Text] [Related]
15. Durability of rifaximin response in hepatic encephalopathy.
Neff GW; Jones M; Broda T; Jonas M; Ravi R; Novick D; Kaiser TE; Kemmer N
J Clin Gastroenterol; 2012 Feb; 46(2):168-71. PubMed ID: 22011586
[TBL] [Abstract][Full Text] [Related]
16. Rifaximin treatment in hepatic encephalopathy.
Sharma P; Sharma BC
N Engl J Med; 2010 Jun; 362(25):2423-4; author reply 2424-5. PubMed ID: 20578274
[No Abstract] [Full Text] [Related]
17. Management of hepatic encephalopathy in the hospital.
Leise MD; Poterucha JJ; Kamath PS; Kim WR
Mayo Clin Proc; 2014 Feb; 89(2):241-53. PubMed ID: 24411831
[TBL] [Abstract][Full Text] [Related]
18. Liver: the gut is a key target of therapy in hepatic encephalopathy.
Sawhney R; Jalan R
Nat Rev Gastroenterol Hepatol; 2015 Jan; 12(1):7-8. PubMed ID: 25348849
[TBL] [Abstract][Full Text] [Related]
19. Add-on Therapeutic Effects of Rifaximin on Treatment-resistant Hepatic Encephalopathy.
Hayakawa Y; Tamaki N; Nakanishi H; Kurosaki M; Tanaka Y; Inada K; Ishido S; Kirino S; Yamashita K; Nobusawa T; Matsumoto H; Kakegawa T; Higuchi M; Takaura K; Tanaka S; Maeyashiki C; Kaneko S; Yasui Y; Takahashi Y; Tsuchiya K; Okamoto R; Izumi N
Intern Med; 2023 Apr; 62(7):973-978. PubMed ID: 36070941
[TBL] [Abstract][Full Text] [Related]
20. Update on the Therapeutic Management of Hepatic Encephalopathy.
Kornerup LS; Gluud LL; Vilstrup H; Dam G
Curr Gastroenterol Rep; 2018 Apr; 20(5):21. PubMed ID: 29644492
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
